NHS Pharmaceuticals 2017_1

Offer reference number: CM/PHG/15/5490

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months.

Potential periods of call-offs under the framework agreement:

North West and Eastern and North London: 1.5.2017 to 31.1.2018 (9 months),

South East and South London and North East and Yorkshire: 1.5.2017 to 31.10.2017 (6 months),

Central and South West: 1.5.2017 to 30.6.2018 (14 months).

NHS Pharmaceuticals Products Transition 2017_1 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months.

Potential periods of call-offs under the framework agreement:

CM/PHG/15/5490/01 — LSNE — 1.5.2017 to 31.10.2017 (6 months),

CM/PHG/15/5490/02 — NWLN — 1.5.2017 to 31.1.2018 (9 months),

CM/PHG/15/5490/03 — CESW — 1.5.2017 to 30.6.2018 (14 months).

NHS Pharmaceuticals Products Transition 2017_1 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months.

Potential periods of call-offs under the framework agreement:

CM/PHG/15/5490/01 — LSNE — 1.5.2017 to 31.10.2017 (6 months),

CM/PHG/15/5490/02 — NWLN — 1.5.2017 to 31.1.2018 (9 months),

CM/PHG/15/5490/03 — CESW — 1.5.2017 to 30.6.2018 (14 months).

NHS Pharmaceuticals Products Transition 2017_1 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months.

Potential periods of call-offs under the framework agreement:

CM/PHG/15/5490/01 — LSNE — 1.5.2017 to 31.10.2017 (6 months),

CM/PHG/15/5490/02 — NWLN — 1.5.2017 to 31.1.2018 (9 months),

CM/PHG/15/5490/03 — CESW — 1.5.2017 to 30.6.2018 (14 months).